Back to Search Start Over

Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders

Authors :
Laura Iarriccio
Rosario Perona
José Luis Pedraz
Fernando Albericio
Daniel Carbajo
Susana P. Egusquiaguirre
Cristina Manguan-García
Manuela Igartua
Rosa Maria Hernandez
Laura Pintado-Berninches
Miriam Royo
Eusko Jaurlaritza
Centro de Investigación Biomédica en Red Enfermedades Raras (España)
Ministerio de Economía y Competitividad (España)
Universidad del País Vasco
Federación Española de Enfermedades Raras
Instituto de Salud Carlos III
Source :
Digital.CSIC. Repositorio Institucional del CSIC, instname
Publication Year :
2014

Abstract

et al.<br />The aim of the present study was to develop a novel strategy to deliver intracellularly the peptide GSE24.2 for the treatment of Dyskeratosis congenita (DC) and other defective telomerase disorders. For this purpose, biodegradable polymeric nanoparticles using poly(lactic-co-glycolic acid) (PLGA NPs) or poly(lactic-co-glycolic acid)-poly ethylene glycol (PLGA-PEG NPs) attached to either polycations or cell-penetrating peptides (CPPs) were prepared in order to increase their cellular uptake. The particles exhibited an adequate size and zeta potential, with good peptide loading and a biphasic pattern obtained in the in vitro release assay, showing an initial burst release and a later sustained release. GSE24.2 structural integrity after encapsulation was assessed using SDS-PAGE, revealing an unaltered peptide after the NPs elaboration. According to the cytotoxicity results, cell viability was not affected by uncoated polymeric NPs, but the incorporation of surface modifiers slightly decreased the viability of cells. The intracellular uptake exhibited a remarkable improvement of the internalization, when the NPs were conjugated to the CPPs. Finally, the bioactivity, addressed by measuring DNA damage rescue and telomerase reactivation, showed that some formulations had the lowest cytotoxicity and highest biological activity. These results proved that GSE24.2-loaded NPs could be delivered to cells, and therefore, become an effective approach for the treatment of DC and other defective telomerase syndromes.<br />Susana P. Egusquiaguirre thanks the Basque Government (Gobierno Vasco, Departamento de Educación, Universidades e Investigación) for the fellowship research grant. C. Manguan-García is supported by CIBER de Enfermedades Raras. This project was partially supported by the Basque Government (Consolidated Groups, IT-407-07), MINECO from the Spanish Government (INNPACTO, IPT-2012-0674-090000). The authors gratefully acknowledge the support of University of the Basque Country UPV/EHU (UFI11/32). Besides, this work was also supported by grant PI11-00949 (supported by FEDER funds) from Instituto Carlos III.

Details

ISSN :
18733441
Volume :
91
Database :
OpenAIRE
Journal :
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Accession number :
edsair.doi.dedup.....e4dc205c711d474c962afe592335450d